Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Clinical impact on treatment effectiveness of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Authors
Keito Suzuki
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino-Shi, Tokyo, Japan
Keito Suzuki , Yutaka Yasui , Kaoru Tsuchiya , Hiroaki Matsumoto , Yudai Yamazaki , Naoki Uchihara , Yuki Tanaka , Haruka Miyamoto , Michiko Yamada , Taisei Keitoku , Risa Okada , Mayu Higuchi , Kenta Takaura , Shohei Tanaka , Chiaki Maeyashiki , Nobuharu Tamaki , Hiroyuki Nakanishi , Yuka Takahashi , Masayuki Kurosaki , Namiki Izumi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 479)
DOI
10.1200/JCO.2024.42.3_suppl.479
Abstract #
479
Poster Bd #
C4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment.
First Author: Jaekyung Cheon
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.
First Author: Claudia A.M. Fulgenzi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
First Author: Changhoon Yoo
Poster
2024 ASCO Annual Meeting
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa